References
- Deer TR , LevyR, PragerJ et al. Polyanalgesic Consensus Conference – 2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation 15 , 467–482 (2012).
- Staats PS , YearwoodT, CharapataS. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized control trial. JAMA291 , 63–70 (2004).
- Hayek S , HanesM. Intrathecal therapy for chronic pain: current trends and future needs. Curr. Pain Headache Rep.18 , 388 (2014).
- Thrasher TA , FisherS. Societal costs of intrathecal drug delivery systems – an administrative analysis based on patient claims. Neuromodulation16(3) , 261–265 (2013).
- Prager J , DeerT, LevyR et al. Best practices for intrathecal drug delivery for pain. Neuromodulation doi:10.1111/ner.12146 (2014) (Epub ahead of print).
- Taira T , UetaT, KatayamaY et al. Rate of complications among the recipients of intrathecal baclofen pump in Japan: a multicenter study. Neuromodulation 16(3) , 266–272 (2013).
- Bulat M , KlaricaM. Recent insights into a new hydrodynamics of the cerebrospinal fluid. Brain Res Rev.65(2) , 99–112 (2011).
- De Andres J , PerottiL, Villanueva Perez V, Asensio-Samper JM, Fabregat-Cid G. Role of catheter‘s position for final results in intrathecal drug delivery. Analysis based on CSF dynamics and specific drugs profiles. Korean J. Pain26(4) , 336–346 (2013).
- Hsu Y , HettiarachchiHD, ZhuDC, LinningerAA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth. Analg.115 , 386–394 (2012).
- Kamran S , WrightBD. Complications of intrathecal drug delivery systems. Neuromodulation4 , 111–115 (2001).
- Zhong Z , QulianG, YuanZ et al. Repeated intrathecal administration of ropivacaine causes neurotoxicity in rats. Anaesth. Intensive Care 37 , 929–936 (2009).
- Wallace MS , RauckR, FisherR et al. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth. Analg. 106 , 628–637 (2008).
- Follett KA , BurchielK, DeerT et al. Prevention of intrathecal drug delivery catheter-related complications. Neuromodulation 6 , 32–41 (2003).
- Gofeld M , McQueenCK. Ultrasound-guided intrathecal pump access and prevention of the pocket fill. Pain Med.12(4) , 607–611 (2011).
- Peccora CD , RossEL, HannaGM. Aberrant intrathecal pump refill: ultrasoundguided aspiration of a substantial quantity of subcutaneous hydromorphone. Reg. Anesth. Pain Med.38(6) , 544–546 (2013).
- Deer T , ProvenzanoD. Recommendations for reducing infection in the practice of implanting spinal cord stimulation and intrathecal drug delivery devices: a physician´s playbook. Pain Physician16 , E125–E128 (2013).
- Engle M , VinhB, HarunN, KoyyalaguntaD. Infectious complications related to intrathecal drug delivery system and spinal cord stimulation system implantations at the comprehensive cancer pain center. Pain Physician16 , 251–257 (2013).